Chronic lymphocytic leukemia (CLL) is a malignant, chronic lymphoproliferative disorder characterized by proliferation and accumulation of monoclonal B-cells in the bone marrow, peripheral blood, lymph nodes, liver and spleen.

It is the most common form of adult leukemia in the Western world but rare in Asians.

Exact etiology is unknown but usually associated with genetic aberrations and lesions.


Follow Up

  • Patients should be re-evaluated every 6 months within the 1st year of diagnosis
  • Physical examination & blood exams are used for assessment of treatment response
    • Bone marrow biopsy & aspirate should be conducted on patients in clinical trials
  • Complete response should include all of the following, at least 2 months after treatment completion:
    • Peripheral blood lymphocyte count <4 x 109/L
    • Normal blood counts without growth factor support (neutrophils >1.5 x 109/L, platelets >100 x 109/L, Hemoglobin >11 g/dL)
    • No enlarged lymph nodes (>1.5 cm in diameter)
    • No splenomegaly or hepatomegaly
    • No constitutional symptoms
  • Partial response criteria includes ≥2 of the following within 2 months duration:
    • ≥50% reduced peripheral blood lymphocyte count, lymphadenopathy, hepatomegaly &/or splenomegaly compared to baseline
    • ≥1 of the blood count normalized or increased by ≥50% from baseline
  • Disease progression involves any of the following:
    • Lymphocyte count, lymphadenopathy, splenomegaly or hepatomegaly increased by 50% from baseline
    • Presence of new lesions or transformation to more aggressive forms
    • Occurrence of cytopenias contributing to chronic lymphocytic leukemia progression (>2 g/dL hemoglobin & >50% platelet count decreased from baseline)
  • Stable disease is defined as disease without complete or partial response but without disease progression
  • Minimal residual disease (MRD)
    • Usually detected by flow cytometry

Management of Relapse

  • Relapsed disease occurs when disease progression appears ≥6 months after initial complete or partial response
  • Refractory disease is when a patient fails to achieve a response or disease progression occurs within 6 months of the last treatment dose

Management of Refractory or Relapsed Chronic Lymphocytic Leukemia

  • Depends on the presence of del(17p)/TP53 mutation, patient’s age, & presence of comorbidities
  • Frail patients without del(17p)/TP53 mutation or ≥65 years old & younger with significant comorbidities
    • Ibrutinib1
    • Idelalisib + Rituximab1
    • Idelalisib2
    • Ofatumumab2
    • Obinutuzumab2
    • Reduced-dose FCR2(Fludarabine, Cyclophosphamide, Rituximab)
    • Reduced-dose PCR2(Pentostatin, Cyclophosphamide, Rituximab)
    • High dose Methylprednisone + Rituximab2
    • Rituximab + Chlorambucil2
    • Bendamustine +/- Rituximab2
    • Lenalidomide +/- Rituximab2
    • Alemtuzumab +/- Rituximab2
    • Dose-dense Rituximab3
    • Venetoclax2
    •  Ibrutinib, Bendamustine, Rituximab4
    • Idelalisib, Bendamustine, Rituximab
  • Chronic lymphocytic leukemia without del(17p)/TP53 mutation <65 years old without significant comorbidities
    • Ibrutinib1
    • Idelalisib + Rituximab1
    • Idelalisib2
    • Ofatumumab2
    • Obinutuzumab2
    • FCR2(Fludarabine, Cyclophosphamide, Rituximab)
    • PCR2(Pentostatin, Cyclophosphamide, Rituximab)
    • Bendamustine +/- Rituximab2
    • FC + Ofatumumab2
    • High dose Methylprednisone + Rituximab2
    • OFAR2 (Oxaliplatin, Fludarabine, Cytarabine, Rituximab)
    • Lenalidomide +/- Rituximab2
    • Alemtuzumab +/- Rituximab2
    • RCHOP2 (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)
    • Venetoclax2
    • Ibrutinib, Bendamustine, Rituximab3
    • Idelalisib, Bendamustine, Rituximab3
  • Chronic lymphocytic leukemia with del(17p)/TP53 mutation
    • Ibrutinib2
    •  Idelalisib + Rituximab2
    • Idelalisib2
    • Ofatumumab2
    • Lenalidomide +/- Rituximab2
    • Alemtuzumab +/- Rituximab2
    • OFAR2(Oxaliplatin, Fludarabine, Cytarabine, Rituximab)
    • High dose Methylprednisone + Rituximab2
    •  Venetoclax2

1Indicated as Category 1 by the National Comprehensive Cancer Network (NCCN).
2Indicated as Category 2A by the National Comprehensive Cancer Network (NCCN).
3Indicated as Category 2B by the National Comprehensive Cancer Network (NCCN).
4Indicated as Category 3 by the National Comprehensive Cancer Network (NCCN).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Stephen Padilla, 24 Oct 2017
Cancer drugs approved by the European Medicines Agency (EMA) from 2009 to 2013 have been sold in the market even without evidence of benefit on survival or quality of life (QoL), according to a study. Survival gains over existing treatment options or placebo, if any, are usually marginal.
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017